SYNOVIAL SARCOMA
Clinical trials for SYNOVIAL SARCOMA explained in plain language.
Never miss a new study
Get alerted when new SYNOVIAL SARCOMA trials appear
Sign up with your email to follow new studies for SYNOVIAL SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental immune therapy targets Tough-to-Treat sarcomas
Disease control OngoingThis study is testing whether a personalized immune cell therapy can help control advanced synovial sarcoma or myxoid liposarcoma. Doctors take a patient's own immune cells, genetically modify them to recognize cancer, and infuse them back. The trial will measure how well tumors …
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for tough sarcomas: adding a targeted drug to standard treatment
Disease control OngoingThis study is for patients with newly diagnosed, high-risk soft tissue sarcomas that can be removed by surgery. It tests whether adding a drug called pazopanib to standard pre-surgery treatments (radiation with or without chemotherapy) helps shrink tumors more effectively and imp…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New hope for kids with tough cancers: scientists test 'Re-Trained' immune cells
Disease control OngoingThis early-stage study is testing a new type of personalized cell therapy for children and young adults whose solid tumors have come back or haven't responded to other treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cance…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New Two-Pronged attack tested against rare cancers before surgery
Disease control OngoingThis early-stage study is testing the safety of combining two immunotherapy drugs, nivolumab and BO-112, given before surgery for patients with operable soft tissue sarcoma. The goal is to see if stimulating the immune system to attack the tumor before it is removed can improve o…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for kids with tough cancers: genetically engineered immune cells target tumors
Disease control OngoingThis early-phase study is testing the safety and feasibility of a new treatment called CAR T-cell therapy for children and young adults whose solid tumors have come back or not responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to be…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Scientists reprogram Patients' own cells to hunt cancer
Disease control OngoingThis early-stage study tests a personalized cell therapy for people with advanced solid tumors. Doctors collect a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer, then infuse them back into the patient. The main goals are to chec…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
First human test of novel cancer vaccine begins
Disease control OngoingThis is an early safety study testing a new cancer vaccine called PeptiCRAd-1, given alongside the immunotherapy drug pembrolizumab. It aims to see if this combination is safe and can activate the immune system to fight cancer in patients with advanced solid tumors that have stop…
Matched conditions: SYNOVIAL SARCOMA
Phase: PHASE1 • Sponsor: Valo Therapeutics Oy • Aim: Disease control
Last updated Mar 03, 2026 14:07 UTC